This content is machine translated Urothelial carcinoma Immune and targeted therapy options: Evidence situation 2025/2026 The treatment of urothelial carcinoma has developed significantly in recent years. Modern immunotherapies, antibody-drug conjugates (ADCs) and targeted substances complement conventional chemotherapies and increasingly enable individualized treatment strategies. New data...…
View Post 3 min This content is machine translated Breast Cancer HER2-negative breast cancer in a pot with triple-negative tumors? One study suggests that patients with low HR-positive/HER2-negative tumors could be considered and treated similarly to patients with triple-negative tumors. Should the current definitions of HR positivity and their clinical…
View Post 7 min This content is machine translated New therapies Progress in metastatic malignant melanoma New insights in tumor biology and immunology as well as in molecular pathology have rapidly driven the development of immunomodulatory antibodies and so-called “targeted” therapeutics [1]. This makes the therapy…
View Post 8 min This content is machine translated New therapies Progress in metastatic malignant melanoma New insights in tumor biology and immunology as well as in molecular pathology have rapidly driven the development of immunomodulatory antibodies and so-called “targeted” therapeutics [1]. This makes the therapy…
